StreetAlpha.app
Home › Stocks › OKUR

OnKure Therapeutics, Inc. (OKUR)

Healthcare
$2.58
▼ −6.18%
LAST CLOSE · NOV 17

OnKure Therapeutics develops small molecule drugs that target mutated forms of the PI3K alpha protein in cancer and other diseases. It last closed at $2.58 on Nov 17, down 6.18% on the day. In the past 30 days there were 1 dark pool print totaling $279K, the largest $279K.

AI Auto Pilots
Is OKUR in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Revenue
$4.1M
+1.7% vs a year ago
Net income
−$61.9M
−1494.7% margin
EPS (diluted)
−$2.26
−102.4% vs a year ago
Free cash flow
−$47.9M
−1158.4% margin
Valuation
Market cap
$104.5M
40.5M shares
P/E
–
No P/E while losing money
Price to sales
25.3
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$151.4M
At Sep 30
Shareholder equity
$157.7M
Shares outstanding
40.5M
At Nov 2
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2023: $1.6M$1.6MFY2023FY2024: $1.7M$1.7MFY2024FY2025: $3.4M$3.4MFY2025

From OKUR's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 4). Last 12 months adds up the four latest quarters.

Next report
—
No date on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
—
No ratings in 90 days
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Consensus · 90 days
No firm has rated OKUR in the past 90 days.
Average 12-month target
No price targets on OKUR in the past 90 days.
Latest rating changes
OppenheimerReiterated
Aug 14Buy$14
HC Wainwright & Co.Maintained
Jul 20Buy$21
DateFirmActionRatingPrice target
Aug 14OppenheimerReiteratedBuy$14
Jul 20HC Wainwright & Co.MaintainedBuy$21
Loading…

Technical Analysis

OKUR · as of the Nov 17 close · updated after every close
Moving sideways

The stock is 5% below its 20 day and 5% below its 50 day average. It is 40% below its 200 day average, so the longer trend is down. Momentum is neutral (RSI 46). The nearest support is the Pivot S1 at $2.49, and the nearest resistance the Pivot at $2.59.

Short trendNeutral
Long trendBearish
MomentumNeutral
StretchNormal
VolatilityHigh, 10.7%/day
Key levels
$5.3852 week high+108.5%
$3.61200 day average+39.9%
$3.38100 day average+31.0%
$2.7220 day average+5.4%
$2.72Swing high (Oct 27)+5.4%
$2.7050 day average+4.7%
$2.69Pivot R1+4.3%
$2.59Pivot+0.4%
$2.58Last close
$2.49Pivot S1−3.5%
$2.31Swing low (Nov 6)−10.5%
$2.0152 week low−22.1%
Indicators
RSI (14)45.67Middle of its rangeNeutral
MACD0.05Below its signal lineBearish
Stochastic26.7Middle of its rangeNeutral
ADX (14)17.5No clear trend
Williams %R-79.0Oversold below −80, overbought above −20Neutral
CCI (20)-33.4Oversold below −100, overbought above 100Neutral
Rate of change+3.2%Change over 10 sessionsBullish
ATR (14)$0.28Typical daily range, 10.8% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for OKUR

What happened before

See how OKUR did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow OKUR usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How OKUR has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2021.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in OKUR in the last 90 days.

Loading…

See today’s whale options flow across the market →

Dark Pool

30D
Prints
1
Notional
$279K
Largest print
$279K
Loading…

OKUR Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bullish
Strongly bearishNeutralStrongly bullish
  • ▲43 buying vs 21 selling
  • ▲Held by funds +1.1 pts
  • ▲Funds holding +8
  • ▼Superinvestors: 0 added, 2 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding8375+10.7%
In funds' top 10220.0%
Held by funds87.4%86.3%+1.1 pts
New / increased12 / 3131 / 21−17.3%
Reduced / sold out17 / 49 / 8+23.5%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See OKUR institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether OKUR is in one of them and how their past OKUR trades turned out.

OKUR in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered OKUR in an article yet. Here's the latest on the wider market.

About OnKure Therapeutics

OnKure Therapeutics is a biopharmaceutical company based in Boulder, Colorado. It develops small molecule drugs that target specific mutated forms of the PI3K alpha protein, a driver of cancer and other diseases, while sparing the normal form of the protein. Its lead candidate, OKI-219, is in Phase 1 clinical trials for patients with advanced breast cancer, and the company is also researching treatments for vascular malformations.

Headquarters
Boulder, CO